Palatin Technologies, Inc. (NYSE American: PTN) today announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist, in obese patients in the first quarter of calendar year 2024.
|
[18-October-2023] |
CRANBURY, N.J., Oct. 18, 2023 /PRNewswire/ -- Palatin Technologies Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist, in obese patients in the first quarter of calendar year 2024. In addition, Palatin announced a poster presentation of preclinical data, entitled Melanocortin receptor 4 agonist PL8905 in Combination with Glucagon Like Peptide-1 Produces Synergistic Weight Loss, Reduced Food Intake, and Greater Glucose Control in Diet-Induced Obese (DIO) Rats (Dodd et al.) at the Peptide Therapeutics Symposium, October 16-17, 2023 in La Jolla, CA. GLP-1 agonists are currently the standard of care treatment for obesity. However, real-world use data shows that more than two-thirds (68%) of obese patients discontinue use in the first year. Side effects, especially at higher dose levels and a plateau effect, contribute to the high discontinuation rate. Palatin’s innovative approach aims to address these issues by improving treatment adherence and promoting consistent long term weight loss through combination therapy. By co-administering an MC4R agonist with a GLP-1 agonist, Palatin anticipates achieving significant weight loss at lower doses, with improved tolerability. Combination drug therapy will be a key part of improving the overall health and quality of life for obese patients. “With the increased use of FDA-approved GLP-1 agonists for treating obesity there is an unmet need for treatments with alternative mechanisms of action that will help obese patients meet and maintain their weight loss objectives. We believe the MC4R agonist is the best validated mechanism for adjunctive therapy with GLP-1 agonists and weight loss maintenance,” said Carl Spana, Ph.D., President and CEO of Palatin. “With our extensive experience in obesity research, a portfolio of novel selective MC4R agonists, and access to bremelanotide, an FDA approved MC4R agonist, we are well positioned to advance an MC4R agonist as a potentially effective and safe treatment for obesity.” The Peptide Therapeutics Symposium poster presented data evaluating the selective MCR4 agonist PL8905 from preclinical studies in which diet-induced obese animals were treated for 5 days with vehicle control, subcutaneous PL8905 alone and in combination with continuous infusion of a GLP-1 agonist.
The use of combination therapy is supported by preclinical data with MC4R agonist PL8905 and two previous clinical studies with MC4R agonist bremelanotide demonstrating statistically significant effects on reducing food intake and weight loss in obese patients (published data; Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes Obes Metab. 2022;1-10. doi:10.1111/dom.14672 is available at www.Palatin.com). Palatin has extensive experience and intellectual property in the design and development of MC4R agonists that can be used as treatments for obesity. This includes novel selective MC4R peptide agonists and oral small molecule MC4R agonists. About Melanocortin 4 Receptor Agonists Effect on Obesity About Obesity About Palatin Forward-looking Statements Palatin Technologies® and Vyleesi® are registered trademarks of Palatin Technologies, Inc. View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-announces-positive-preclinical-data-showing-synergistic-weight-loss-initiating-clinical-study-of-melanocortin-4-receptor-agonist--glp-1-in-obese-patients-301960009.html SOURCE Palatin Technologies, Inc. | ||
Company Codes: AMEX:PTN |